Come stop by to see CPP as we will be exhibiting alongside Nationwide Children’s Hospital (booth # 1425) in the exhibit hall during the conference!
Come stop by the CPP Buying Group booth (# 425) in the exhibit hall during the conference!
CPP will also be sponsoring the Independent/Solo Small Practice Member Interest Group meeting on Friday, September 23 from 12:30PM-2:30PM. We will be sharing information and resources related to vaccine management with all of the attendees!
Since the FDA approval of Gardasil 9 in late 2014, CPP members have been steadily converting from Gardasil to Gardasil 9 as the preferred HPV vaccine for their patients.
Effective October 31, 2016, Merck will no longer sell Gardasil. This decision is not related to any product safety or manufacturing issues with Gardasil and all existing inventories will be depleted. Any unused Gardasil doses can be returned to Merck for credit after their expiration date, in accordance with the Merck Return Policy.
Please note that GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) is available and is not impacted by this action.
We are excited to announce a new partnership between CPP and Pfizer that will provide CPP members an opportunity to save on purchases of Trumenba®, a meningococcal group B vaccine! In order to receive the CPP discount, doses must be purchased directly from Pfizer using your Pfizer account.
For exact details regarding this savings opportunity and to obtain a copy of the opt-in form for this portion of the CPP program, please contact the CPP office at 614-722-2145 or email@example.com.
At the June 22 meeting of the ACIP, preliminary data were shared regarding the effectiveness of FluMist® Quadrivalent during the 2015-2016 influenza season. Based on a review of these data, the ACIP issued an interim recommendation that FluMist Quadrivalent should not be used in any setting for the 2016-2017 influenza season.
Our goal in sharing this information with you is to ensure you are fully informed as you plan for the upcoming 2016-2017 influenza season. AstraZeneca will continue to evaluate the decision of making FluMist Quadrivalent available within the United States in the 2016-17 influenza season and will be providing additional information. At this time you may reach out to your FluMist Quadrivalent distributor to make any order modifications you feel are necessary.
The APP has pulled together some resources to help your practice through the transition. Click here for more details.
Beginning in July 2016, Merck will experience a supply disruption to the syringe presentation of GARDASIL® 9, pediatric formulations of RECOMBIVAX® HB and VAQTA® as well as adult formulation of RECOMBIVAX® HB. Please note that only the syringes have been affected and the suppy disruption does not include vial formulations. Merck anticipates that supplies of the syringes will be depleted until the second quarter of 2017.
Sanofi Pasteur has announced a pricing promotion on Menactra®! CPP members will receive an additional 3% discount on orders of Menactra® placed before June 24th and shipped by June 28th.
In addition, the CPP contracted price for Adacel® has DECREASED 4% effective June 10, 2016. For updated pricing sheets on all Sanofi Pasteur vaccines, please contact the CPP office.